Skip to content

Gyrocardiography- A New Non-invasive Cardiac Measurement Method to Measure Exercise Capacity and Cardiorespiratory Fitness

Gyrocardiography- A New Non-invasive Cardiac Measurement Method to Measure Exercise Capacity and Cardiorespiratory Fitness

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05936827
Enrollment
102
Registered
2023-07-10
Start date
2023-03-01
Completion date
2024-12-31
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The goal of this study is to produce a solution to measure the cardiorespiratory fitness (CRF), which can be used by commercially available smartphones without extra equipment, add-ons and special know-how. This observational study with follow-up is to test the feasibility of a new non-invasive cardiac measurement method (gyrocardiography, GCG) in detecting hemodynamic parameters to measure exercise capacity and cardiorespiratory fitness in healthy subjects. The objective is to produce a solution which can be used to measure the exercise capacity and cardiorespiratory fitness (CRF) of the exercisers, keep-fit athletes and professional athletes using hemodynamic parameters such as: * Heart rate and Heart rate variability * Cardiac Strength profile * Systolic and diastolic phase * Breathing frequency * VO2max Participants are either athletes or non-athletic persons. The athletes will perform spiroergometry and non-athletic persons ergometry to measure the CRF expressed as VO2max. Following parameters will be measured during the (spiro)ergometry: * Maximum workload (W) * VO2max (ml/kg/min) * HRmax * Blood lactate * Respiratory exchange ratio RER (VO2/VCO2) The GCG measurements for acquiring the hemodynamic parameters are performed before and after the (spiro)ergometry using smartphone. During a 1- minute GCG measurement, the smart phone is placed on the chest in the middle of the sternum.

Interventions

DIAGNOSTIC_TESTErgometry

Maximal exercise test is performed on a cycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany). The test begins at a workload of 50 W, which is increased by 25 W (males) every 1 min or the test begins with 25 W which is increased by 25 W (females) every 1 min until exhaustion. The mean workload during the last 4 min of work is calculated and the VO2max is estimated according to the American College of Sports Medicine (American College of Sports Medicine. ACSM's guidelines for exercise testing and prescription. Sixth edition. Baltimore: Williams & Wilkins 2000:304). Blood lactate concentration is measured immediately and 1 min after exhaustion from capillary samples (Biosen C-Line Glucose and Lactate analyzer, EKFdiagnostic GmbH, Germany). (Pahkala et al. 2013.)

DIAGNOSTIC_TESTErgospirometry

VO2max is measured using a stationary bicycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany. For males, the test starts with 100 W which is increased by 25 W every 1 min until volitional exhaustion. For females, the test starts with 50 W which is increased by 25 W every 1 min until volitional exhaustion. Ventilation and gas exchange (Vyntus CPX, Vyaire Medical Gmbh, Leibnizstrasse, Hoechberg, Germany) are measured during the test. Subject's blood lactate concentration is measured from capillary samples immediately and 1 min after exhaustion (Biosen C-Line Glucose and Lactate analyzer, EKF-diagnostic GmbH, Germany). The heart rate of the participants is followed continuously (CardioSoft GE, CardioSoft V6.51; GE Medical Systems Information Technologies, USA). (Heiskanen et al. 2021.)

Sponsors

Paavo Nurmi Centre
CollaboratorUNKNOWN
Precordior Ltd
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Age: 18-65 years * No diagnosed cardiovascular diseases (mild hypertension or hypercholesterolemia are still allowed) * No medication affecting heart rate (i.e. Beta blocker) * Signed informed consent Follow-up visit: * Belong to non-athletic group * Intention to change physical activity habits * Willing to participate to the follow-up visit

Exclusion criteria

* Not meeting inclusion criteria * Declined to participate * Resting RR before the ergometry \> 180/110mmHg

Design outcomes

Primary

MeasureTime frameDescription
The maximum (max) rate (V) of oxygen (O₂) your body is able to use during exercise.4 minutes
Gyrocardiography measurement1 minuteLasts 1 minute and is performed at least once at rest before the (spiro)ergometry.

Secondary

MeasureTime frameDescription
Heart rate per minute and Heart rate variability1 minuteLasts 1 minute and is performed at least once at rest before the (spiro)ergometry.
Systolic and diastolic phase (blood pressure RR)1 minuteWill be performed at least once at rest before the (spiro)ergometry.
Respiration rate per minute1 minuteLasts 1 minute and is performed at least once at rest before the (spiro)ergometry.
Cardiac Strength profile1 minuteLasts 1 minute and is performed at least once at rest before the (spiro)ergometry.

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026